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Abstract: Fibromyalgia syndrome (FMS) is a widespread pain condition associated with fatigue, 
cognitive dysfunction, sleep disturbance, depression, anxiety, and stiffness. Milnacipran is one 
of three medications currently approved by the Food and Drug Administration in the United 
States for the management of adult FMS patients. This review is the second in a three-part series 
reviewing each of the approved FMS drugs and serves as a primer on the use of milnacipran in 
FMS treatment including information on pharmacology, pharmacokinetics, safety and tolerability. 
Milnacipran is a mixed serotonin and norepinephrine reuptake inhibitor thought to improve FMS 
symptoms by increasing neurotransmitter levels in descending central nervous system inhibitory 
pathways. Milnacipran has proven efficacy in managing global FMS symptoms and pain as well 
as improving symptoms of fatigue and cognitive dysfunction without affecting sleep. Due to 
its antidepressant activity, milnacipran can also be beneficial to FMS patients with coexisting 
depression. However, side effects can limit milnacipran tolerability in FMS patients due to its 
association with headache, nausea, tachycardia, hyper- and hypotension, and increased risk 
for bleeding and suicidality in at-risk patients. Tolerability can be maximized by starting at 
low dose and slowly up-titrating if needed. As with all medications used in FMS management, 
milnacipran works best when used as part of an individualized treatment regimen that includes 
resistance and aerobic exercise, patient education and behavioral therapies.
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Introduction to fibromyalgia diagnosis  
and management
Fibromyalgia syndrome (FMS) is a disorder of chronic widespread pain (CWP) 
associated with fatigue, sleep disturbance, depression, anxiety, cognitive dysfunction 
and muscle and joint stiffness.1 FMS affects patients worldwide, with an estimated 
prevalence in developed countries that ranges from 0.5% to 5.8%.2 FMS can exist as 
a primary disorder or may occur secondarily in association with a variety of chronic 
medical conditions. While FMS is not an inflammatory disorder, it is commonly seen 
in association with inflammatory autoimmune diseases such as rheumatoid arthritis 
and systemic lupus erythematosus.3,4 The most widely used criteria for identifying 
FMS patients is the American College of Rheumatology (ACR) 1990 classification 
criteria.5 However use of the ACR criteria for FMS diagnosis is discouraged,6 since 
the ACR criteria lack sensitivity and fail to recognize associated FMS symptoms 
that must be addressed to optimally manage the disorder.7 Recently proposed FMS 
clinical diagnostic criteria that identify patients based on the number of somatic 
symptoms and painful body areas along with severity of symptoms of fatigue, sleep Journal of Pain Research 2010:3 16
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disturbance and cognitive dysfunction may eventually 
improve FMS diagnosis.8 Pending finalization of diagnostic 
criteria, we recommend assessment and treatment of all 
patients with CWP for associated FMS symptoms. These 
symptoms can be recalled using the “FIBRO” mnemonic, 
where F = Fatigue and/or Fibrofog (cognitive dysfunction), 
I = Insomnia (nonrestorative sleep), B = Blues (depression 
and/or anxiety), R = rigidity (stiffness in muscles and/or 
joints) and O = Ow! (pain and work difficulty).9 Question-
naires such as the mVASFIQ9 or the SIQR10 can be used 
to assess “FIBRO” symptoms and provide the basis for an 
individualized, symptom-based treatment approach to FMS 
management consistent with evidence-based guidelines.7
Three general points should be kept in mind when treating 
FMS patients. First, primary disorders that can mimic FMS 
must be ruled out before symptomatic therapies are used. 
These include vitamin deficiencies, anemia, and metabolic, 
oncologic, inflammatory or sleep disorders. Second, since 
the majority of FMS patients suffer from multiple medica-
tion intolerances, medications should be started individually 
at low dose and slowly uptitrated and/or combined. Finally, 
while this review focuses on pharmacologic treatment of FMS 
with milnacipran, medications have a limited role in FMS 
management. Medications work best when they are used to 
provide symptomatic relief so that patients can participate in 
nonpharmacologic modalities that provide long-term disease 
coping strategies including aerobic and resistance exercise, 
education, and cognitive behavioral therapies.
Fibromyalgia pathogenesis
While FMS was initially considered a disorder of peripheral 
myofascial tissue, this has been proven incorrect. FMS is a 
neurologic disorder caused by aberrant processing of pain 
and other sensory information within the central nervous 
system (CNS).11 The concept of FMS as a centrally-mediated 
disorder has arisen from numerous scientific studies includ-
ing functional neuroimaging of FMS patients showing that 
brain regions involved in pain processing are hyperactive 
compared to controls.12–14 Serotonin and norepinephrine are 
known to provide important inhibitory signals in regulating 
pain processing pathways,15 and FMS patients have reduced 
levels of norepinephrine and serotonin in their cerebrospi-
nal fluid.16 Augmentation of serotonin and norepinephrine 
CNS activity is thought to be the mechanisms by which 
norepinephrine–serotonin reuptake inhibitor (NSRI) medica-
tions like milnacipran and serotonin – norepinephrine reup-
take inhibitor (SNRI) medications like duloxetine decrease 
FMS pain. However, FMS patients are very heterogeneous 
and it is unlikely that a single pathogenic mechanism is 
responsible for causing FMS in all patients. No single treat-
ment has been found that is effective for all FMS symptoms,17 
and individual FMS patients often respond best to different 
therapies. Also, the serotonin selective reuptake inhibitors 
(SSRIs) have shown mixed results in managing FMS.18 It is 
generally accepted that these mixed results are due to the fact 
that different SSRIs have widely varying concomitant norepi-
nephrine reuptake inhibition (NRI) activity, and it is thought 
to be the NRI activity that is responsible for analgesia. Nor-
epinephrine has an important role in pain modulation that is 
supported by research showing that SNRIs have analgesic 
effects in animal models of central pain that highly selective 
SSRIs lack.19 The balanced ratio of serotonin:norepinephrine 
reuptake inhibition provided by milnacipran is the likely 
reason for its analgesic properties (Table 1).20,21
Overview of pharmacology, mode  
of action and pharmacokinetics  
of milnacipran
Milnacipran is one of three Food and Drug Administra-
tion (FDA)-approved medications for the management of 
FMS. The approved milnacipran dose is 100 or 200 mg 
divided twice daily. Milnacipran is characterized as an 
NSRI because in vitro studies have shown milnacipran has 
a three-fold greater efficacy for inhibiting norepinephrine 
reuptake compared to serotonin, which differentiates it 
from the SNRIs which are more serotonin active (Table 1).23 
However, measurement of relative reuptake inhibition is 
difficult and variability exists for reported values in the 
literature. Also, the relative reuptake inhibition observed 
in vitro may not have physiologic relevance in vivo. For 
instance, while duloxetine is considered a dual reuptake 
Table 1 Relative 5-HT:Ne in-vitro reuptake inhibition of SNRi-
active drugs
Drug name 5-HT:NE reuptake   
inhibition ratio
venlafaxine 30:1
Duloxetine 10:1
Desvenlafaxine 10:1
Amitriptyline 8:1
Milnacipran 1:1
Used with permission from Scholtz BA, Hammonds CL, Boomershine CS. Duloxetine 
for the management of fibromyalgia syndrome. J Pain Res. 2009; 2:99–108.22 Copyright 
© 2009 Dove Medical Press.
Abbreviations: 5-HT, serotonin; Ne, norepinephrine; SNRi, serotonin–norepinephrine 
reuptake inhibitor.Journal of Pain Research 2010:3 17
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inhibitor based on its in vitro activity, one study showed 
no effect on norepinephrine reuptake in vivo as determined 
by response to tyramine infusion in normal subjects.24 
Our clinical experience with dual reuptake inhibitors has 
been that individual FMS patients tend to respond best to 
a specific SNRI and the relative reuptake inhibition ratio 
does not appear to predict therapeutic response (ie, some 
patients who have no response to duloxetine do well on 
milnacipran and vice versa). Unfortunately, the inability 
to predict treatment response usually necessitates multiple 
therapeutic trials before an efficacious drug is found. 
A rational method for drug selection will likely require 
improved understanding of the mechanism(s) of action 
of dual reuptake inhibitors together with patient pharma-
cogenomic data.
Milnacipran has limited hepatic metabolism.25 Approxi-
mately 50% of administered drug is excreted unchanged, 
30% undergoes glucuronidation and 20% is oxidatively 
metabolized. The interaction between milnacipran and 
the cytochrome P450 (CYP) isoenzymes is limited, with 
no interaction with CYP2D6 or CYP2C19 pathways and 
minimal interaction with CYP1A2, CYP2C19, CYP2D6 
and CYP3A4. This is in contrast to duloxetine, which is 
extensively metabolized by the liver and has interactions 
with numerous CYP isoenzymes.26 The differences in 
CYP interactions are the reason that no dose adjustment 
is necessary for milnacipran use in patients with hepatic 
insufficiency,27 whereas duloxetine use in patients with 
hepatic insufficiency is not recommended.28 However, there 
have been cases of increased liver enzymes and reports of 
severe liver injury with milnacipran use in foreign post-
marketing experience. Because of this, we recommend 
routine lab monitoring and discontinuation of milnacipran 
in patients who demonstrate evidence of liver dysfunc-
tion. Concomitant use of hepatotoxic substances with 
milnacipran should be avoided, and milnacipran should 
not be prescribed to patients with substantial alcohol use 
or chronic liver disease.
Milnacipran can be used without dosage adjustment 
in patients with mild to moderate renal insufficiency 
(ie, a creatinine clearance (CrCl)  30 mL/min).29 
Milnacipran can also be used in patients with severe renal 
impairment (ie, a CrCl between 5 and 29 mL/min) if the 
dose is reduced by 50%. This is an important difference 
between milnacipran and duloxetine, as duloxetine 
use is not recommended in patients with severe renal 
impairment.28 Also, due to its limited hepatic metabolism 
and lower protein binding in plasma (∼13% versus 90%, 
respectively), milnacipran has fewer drug-drug interactions 
compared with duloxetine.28,30
Safety and tolerability  
in fibromyalgia syndrome patients
The treatment-emergent adverse events (TEAEs) seen in 
the milnacipran FMS trials are related to NSRI activity and 
are similar to those seen with the SNRIs.30 Gastrointesti-
nal disorders are the most frequent TEAEs, with nausea 
occurring in 35% and 39% of patients treated with 100 and 
200 mg/day of milnacipran, respectively, compared to 20% 
of placebo-treated patients. Nervous system disorders were 
also commonly seen TEAEs, with headache reported by 18% 
of milnacipran-treated patients versus 14% of placebo con-
trols. The noradrenergic activity of milnacipran is apparent 
in the increased rates of hot flushes, hyperhidrosis and pal-
pitations reported by milnacipran treated patients versus that 
seen in controls (12%, 9% and 7% for milnacipran treated 
patients, respectively, versus a 2% rate for all these TEAEs 
in controls). While heart rate and blood pressure increases 
were seen at an increased rate in milnacipran-treated patients 
(6 and 3% for milnacipran treated patients versus 1% in 
controls for both TEAEs), these changes were mild and not 
deemed clinically significant on average. However, since 
the effect of milnacipran on blood pressure and heart rate in 
individual patients cannot be predicted, it is recommended 
that blood pressure and heart rate be regularly monitored in 
patients treated with milnacipran. Other common TEAEs 
(incidence 5% and twice the placebo rate) include con-
stipation, vomiting and dry mouth.
In placebo-controlled FMS trials, 23% of patients treated 
with milnacipran 100 mg/day and 26% of patients treated 
with milnacipran 200 mg/day discontinued prematurely due 
to TEAEs, compared to only 12% of patients treated with 
placebo.30 Nausea was the most frequently cited reason for 
discontinuation in milnacipran treatment groups (6%), fol-
lowed by palpitations (3%), and headache (2%). Milnacipran 
treated patients tended to have weight loss during clinical 
trials that was higher than that seen in placebo-treated 
patients, however the difference was small (0.8 versus 0.2 kg, 
respectively). It is likely the weight loss seen was due to 
the high prevalence of nausea seen in milnacipran treated 
patients. Nausea is a common TEAE seen with SNRI use in 
FMS patients, and its prevalence and severity can be lessened 
by having patients take milnacipran with food and through 
gradual dose escalation.31,32
One of the milnacipran FMS trials specifically mentioned 
that TEAEs were dose related and typically resolved within Journal of Pain Research 2010:3 18
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1 to 2 weeks of continued therapy,33 an observation consistent 
with our clinical experience. The indicated dose of milnacip-
ran for management of FMS is 100 or 200 mg divided twice 
daily. However, we have found that many patients have good 
efficacy with better tolerability when milnacipran is slowly 
uptitrated. We start with 12.5 mg once daily in the morning 
for one week, increase to 25 mg once daily in the morning 
for 2 weeks, and then 50 mg once daily in the morning. Some 
patients have good efficacy with less than the indicated dose 
and we do not up-titrate unless necessary. If insufficient 
clinical efficacy is seen but the drug remains well tolerated, 
we will add an evening dose with slow uptitration as above. 
We will discuss other tolerability observations along with a 
review of milnacipran efficacy in the next section.
Efficacy of milnacipran  
in fibromyalgia syndrome patients
To determine what evidence exists for the efficacy of 
milnacipran in treating FMS, we performed a search of 
Medline and Cochrane Library databases through September 
2009 for randomized-control trials using the key words 
milnacipran and fibromyalgia limiting results to those in the 
English language. There were four published studies identified 
by the search,33–36 the results of which are summarized below 
and in Table 2. It should be noted that none of the milnacip-
ran trials utilized a placebo run-in phase to exclude placebo 
responders, as was done in trials of pregabalin, since these 
run-in phases can have important implications for external 
validity.
Studies 1 and 2: The first two studies will be discussed 
together since they are separate reports of the same study.34,35 
We will limit our discussion to results from the later report 
by Gendreau et al since a more conservative analysis of the 
data was used than that in the earlier report.35 The study was 
a 12 week double-blind, randomized, placebo-controlled, 
dose-ranging, multi-center (14 sites “experienced in treat-
ing” FMS) trial performed in the US comparing milnacipran 
to placebo in patients with FMS. Inclusion criteria required 
adult patients to meet the 1990 ACR classification crite-
ria for FMS,5 have a pain score of 10 on the 20-point 
Gracely logarithmic pain scale, and be willing to discon-
tinue all CNS-active therapies (although stable doses of 
aspirin, acetaminophen and NSAIDs were allowed during 
the study). Exclusion criteria included psychosis; active 
suicidality; alcohol or substance abuse; concurrent auto-
immune, inflammatory, infectious, or malignant disease; 
known sleep apnea; or abnormal baseline liver or kidney 
function tests.
The study included 125 subjects composed almost 
entirely of female Caucasians. The subjects recorded pain 
during a 2-week baseline phase and were then randomized 
in a 3:3:2 ratio to receive milnacipran 25 mg once daily, 
milnacipran 12.5 mg twice daily, or placebo with all patients 
receiving capsules twice daily. Milnacipran dose was upti-
trated as tolerated in weekly intervals up to a maximum of 
200 mg/day over 4 weeks with the ability to decrease the dose 
if dose-limiting toxicities (DLT) occurred. The patients then 
continued at the maximum tolerable dose for an additional 
8 weeks. The primary endpoint was change in average daily 
patient self-reported pain scores over the final 2 weeks of 
the trial compared to the 2-week baseline period. To elimi-
nate bias involved in asking individuals to recall symptoms 
and to improve compliance,37 an innovative system using 
Palm®-based electronic diaries (e-diaries) was employed to 
measured pain level through Gracely’s anchored logarithmic 
scale (0 to 20).38 Patients were asked to rate pain level in the 
e-diaries each morning, retrospectively once weekly, and in 
response to 4 to 6 random prompts. Patients also completed 
standard paper questionnaires to assess pain in monthly inter-
vals using the McGill pain questionnaire and Gracely pain 
intensity scale. At the end of the study, patients completed the 
patient global impression of change (PGIC) scale and numer-
ous secondary endpoints were assessed to determine the 
impact of once-daily and twice-daily milnacipran on fatigue, 
mood, physical function, sleep quality and global function 
as determined by the fibromyalgia impact questionnaire,39 
the Medical Outcomes Study Short Form 36 (SF-36),40 the 
Beck depression inventory,41 the Jenkins sleep scale,42 and 
the Arizona sexual experience scale.43 An intention to treat 
analysis with last observation carried forward was used for 
data analysis.
Subjects receiving milnacipran dosed twice daily 
reported significantly better pain relief than those receiving 
milnacipran once daily, but in other parameters the once-
daily and twice-daily dosing regimens were similar. Thirty-
seven percent of milnacipran subjects dosed twice daily 
reported at least a 50% reduction in pain intensity compared 
with only 22% of subjects receiving milnacipran once daily 
and 14% of those receiving placebo. There was a statistically 
significant difference seen when comparing the percent of 
subjects who rated some degree of improvement in endpoint 
PGIC ratings between milnacipran and placebo treatment 
(73% for twice daily and 77% for once-daily milnacipran 
treatment versus 38% for placebo). While no differences 
were seen for changes in FIQ global scores, milnacipran-
treated subjects reported significant increases in the number Journal of Pain Research 2010:3 19
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of days they “felt good” and the FIQ VASs for pain, fatigue 
and stiffness were significantly improved by milnacipran 
treatment along with improvements in physical function 
scores that neared statistical significance (P = 0.074). This 
is in contrast to results from the SF-36, Jenkins and ASEX 
scores which showed no significant improvements in self-
reported physical function, sleep quality, or sexual function, 
respectively. However, it must be noted that randomization 
of patients with baseline comorbid depression as determined 
by the Mini International Neuropsychiatric Interview (MINI) 
was not consistent across treatment groups (placebo 32%, 
milnacipran twice daily 16% and once daily 7%). This may 
have significantly affected the results as, similar to numer-
ous other studies,44 the authors found depressed subjects had 
significantly higher placebo response rates and it is likely 
the differences would have been larger if depressed patients 
had been equally distributed.
The main importance of this study was that it proved the 
efficacy of milnacipran for managing FMS and that twice-
daily dosing was more efficacious than once-daily dosing. 
It also showed that milnacipran was well tolerated, with no 
significant difference in dropout rates between active drug 
and placebo. Nearly all patients completing the trial (81% of 
once daily and 92% of twice-daily participants) achieved dose 
escalation to the maximum of 200 mg daily. These results set 
the stage for future phase 3 trials that ultimately led to the 
FDA approval of milnacipran for FMS management.
Study 3: This 15-week, multicenter (86 centers in US), 
double-blind, placebo-controlled, fixed-dose trial compared 
milnacipran 100 mg and 200 mg divided twice daily.36 As 
in the Gendreau et al study,35 subjects were required to meet 
the ACR 1990 criteria for FMS;5 in contrast, a linear rather 
than logarithmic VAS pain scale was used to ensure included 
subjects had significant pain at baseline (40 on a linear 0 
to 100 VAS pain scale), making the inclusion criteria similar 
to that used in FMS trials of the other FDA-approved agents. 
Also contrary to the Gendreau et al study,35 subjects with a 
current major depressive episode as determined by the MINI 
were excluded from participation, but similar exclusions 
included severe psychiatric illness; active suicidality; abuse 
of alcohol, benzodiazepines or other substances; a history of 
non-compliant behavior; active cardiovascular, pulmonary, 
hepatic, renal, gastrointestinal, or autoimmune disease; cur-
rent systemic infection; active cancer; unstable endocrine dis-
ease; severe sleep apnea; prostate enlargement or other male 
genitourinary disorder; pregnancy or breastfeeding. As in the 
Gendreau et al study, patients were required to discontinue 
any centrally-acting medications that might interfere with the 
evaluation of pain or other symptoms associated with FMS. 
However, contrary to the Gendreau et al study and all other 
FMS trials of indicated agents, patients were allowed up to 
60 mg/day of hydrocodone as a rescue analgesic therapy 
provided it was not used during the 2-week data-collection 
period preceding the primary efficacy evaluation or during 
the 48-hour period immediately before study visits. This 
provision for opioid use during the study is surprising, as 
treatment trials used to obtain FDA approval of the other 
indicated FMS medications only allowed for acetaminophen 
as a rescue analgesic. Also, narcotic use in treating FMS is 
actively discouraged to prevent the development of rebound 
pain that can lead to dependence.
After a 2-week baseline period, subjects were randomized 
to receive milnacipran or placebo tablets twice daily with 
food. Doses were escalated over the course of 2 to 3 weeks 
to 50 mg twice daily (100 mg/day) or 100 mg twice daily 
(200 mg/day) and continued through 15 weeks total. The 
primary endpoints in this study were different from those used 
in prior FMS studies and evaluated composite response rates 
to investigate the ability of milnacipran to manage global 
FMS symptoms as well as FMS pain. FMS global compos-
ite responders were defined as subjects who simultaneously 
experienced clinically meaningful improvement in pain (30% 
or greater improvement in average morning VAS pain e-diary 
scores for final 2 weeks), global status (much or very much 
improved on the endpoint PGIC scale), and physical function 
(improvement of 6 points on the SF-36 physical component 
summary scale from baseline to week 15). FMS pain compos-
ite responders were defined as those who had improvement 
in pain and global status as defined above. It is important to 
realize these composite response outcomes are more difficult 
to achieve than the primary outcomes that were studied in 
the trials used to obtain FDA approval of the other indicated 
FMS medications which looked solely at reduction in pain. 
Secondary end points included time-weighted averages of the 
individual components of the composite responder analyses 
as well as improvement in sleep quality, cognitive function 
and fatigue. For the primary endpoints, missing data were 
handled using baseline-observation-carried forward (BOCF) 
methodology. BOCF is a much more conservative methodol-
ogy than the more commonly used last-observation-carried 
forward (LOCF) method, and for this reason BOCF is now 
being required instead of LOCF by the FDA for approval 
trials. However, the study authors also reported LOCF and 
observed cases (OC) analyses. OC analysis only includes 
data from trial subjects who fully completed the trial with no 
missing values and is thought to better reflect the treatment Journal of Pain Research 2010:3 21
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response that can be expected clinically in patients who 
tolerate the drug.
Primary analysis included 1196 subjects with approxi-
mately equal numbers randomized to each treatment group. 
Both primary endpoints were met, with a significantly 
greater proportion of subjects in the milnacipran treatment 
groups achieving FMS global (15% 100 mg/day, 14% 
200 mg/day versus 9% placebo) and pain (23% 100 mg/day, 
25% 200 mg/day versus 17% placebo) composite response 
outcome rates compared to those receiving placebo using 
BOCF. While the responder percentages from BOCF analysis 
were small, the more clinically relevant OC analyses showed 
about one-quarter of milnacipran treated subjects achieved 
FMS global composite response rates (25% 100 mg/day, 
26% 200 mg/day versus 13% for placebo) and nearly half 
had a FMS pain composite response (39% 100 mg/day, 46% 
200 mg/day versus 25% for placebo), rates similar to our 
clinical experience. The authors also noted that analgesic 
response to milnacipran began as early as one week after 
starting treatment. This time was during the dose-escalation 
phase, and this observation is consistent with our clinical expe-
rience of many patients responding to lower than indicated 
milnacipran doses. A published extension study indicates the 
efficacy of milnacipran in improving FMS symptoms may 
be sustainable for up to 1 year.45 In analysis of secondary 
endpoints, both milnacipran doses were associated with 
significant improvements in fatigue but only the 200 mg/day 
dose improved cognitive dysfunction. There was no significant 
effect of milnacipran on sleep quality. This is somewhat sur-
prising as other dual reuptake inhibitors including duloxetine 
have been associated with insomnia, presumably due to their 
noradrenergic activity. Since the majority of FMS patients 
have nonrestorative sleep, it is reassuring that milnacipran 
treatment does not appear to worsen sleep quality.
Study 4: The most recently published milnacipran study 
was a fixed-dose, multicenter (59 centers), randomized, pla-
cebo-control trial. Study 4 was very similar to Study 3 but 
lasted twice as long (27 weeks) to show the benefits of mil-
nacipran treatment are maintained over time.33 The strategy of 
performing a 3-month trial to demonstrate efficacy followed 
by a six month trial to show durability has now been used to 
gain FDA approval of all three indicated FMS medications. 
Inclusion and exclusion criteria were similar to those used in 
Study 3, except that patients were required to have baseline 
VAS pain scale scores 50 on a linear 0–100 scale (slightly 
higher than the typical 40 scores required in Study 3 and 
other pain studies). While milnacipran dosing was identical to 
that used in Study 3, Study 4 randomized fewer subjects (888) 
and distributed them unequally between treatment groups 
using a 2:1:1 ratio between the 200 mg/day, 100 mg/day, 
and placebo, respectively. Primary outcomes were the same 
as those in Study 3, with composite responder rates used to 
demonstrate improvement in FMS global symptoms (simul-
taneous improvement in pain [30% or greater improvement in 
average morning VAS pain e-diary scores for final 2 weeks], 
global status (much or very much improved on the endpoint 
PGIC scale), and physical function (improvement of 6 
points on the SF-36 physical component summary scale 
from baseline to week 27)] and improvement in FMS pain 
(simultaneous improvement in VAS pain e-diary and PGIC 
scores as defined above). Secondary end points were also 
identical to those used in Study 3 and included time-weighted 
averages of the individual components of the composite 
responder analyses as well as improvement in sleep quality, 
cognitive function and fatigue. In contrast to study 3 where 
strict BOCF analysis was used, a modified BOCF methodol-
ogy was utilized for imputing missing data in Study 4, with 
BOCF used for patients who discontinued the trial before 
week 15 and LOCF used for patients who discontinued after 
week 15. However, as before, the study authors also reported 
LOCF and OC data analyses. Secondary outcomes were 
identical to those used in Study 3 and included changes in 
fatigue, sleep quality and cognitive function.
In contrast to Study 3, Study 4 did not meet its primary 
endpoints at 27 weeks. While a higher percentage of mil-
nacipran treated FMS subjects achieved the predetermined 
FMS global composite response outcome compared to 
placebo (18.3% for 100 mg/day and 18.1% for 200 mg/day 
versus 13% for placebo), the differences were not statistically 
significant. The FMS pain composite outcome was met for the 
200 mg/day milnacipran group, as significantly more of these 
subjects reached this endpoint compared with placebo (25.6% 
versus 18.4%, P = 0.034). While the 100 mg/day group had a 
responder rate that was higher than the rate in the 200 mg/day 
group (26.8% versus 25.9%, respectively), this difference 
failed to reach statistical significance in comparison to pla-
cebo, likely caused by lower statistical power due to the lower 
number of subjects in the 100 mg/day versus 200 mg/day 
group. Using the more clinically relevant OC comparison 
that limits analysis to patients who completed the trial, the 
200 mg/day milnacipran treatment group met both primary 
outcomes, but the 100 mg/day group only met the FMS pain 
composite response outcome. In secondary endpoint analyses 
using LOCF analysis, milnacipran at 200 mg/day signifi-
cantly reduced fatigue compared to placebo at both 15- and 
27-week time points. While the 100 mg/day dose improved Journal of Pain Research 2010:3 22
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fatigue scores at 15 weeks, statistical significance compared 
to placebo was lost at 27 weeks likely due to the lower num-
ber of patients in the 100 mg/day versus 200 mg/day group 
and a higher placebo response rate observed at the last visit. 
Patients treated with milnacipran at 200 mg/day had signifi-
cant improvement in cognition compared to placebo at both 
15 and 27 week endpoints. While the 100 mg/day dose also 
improved cognition, the differences were not statistically sig-
nificant. As in Study 3, there were no statistically significant 
effects on sleep quality for the milnacipran treatment groups 
compared to placebo.
Forty-two percent of randomized patients prematurely 
discontinued the study, which is a rate higher than that seen 
in the other milnacipran studies. However, this was a longer 
study and similar high discontinuation rates have been seen 
in other 6 month FMS studies.46–49 Also, the rates of seri-
ous TEAEs did not differ across treatment groups. Despite 
these caveats, higher discontinuation rates due to TEAEs 
were seen in the milnacipran versus placebo arms (27% for 
200 mg/day and 19.6% for 100 mg/day versus 10.3% for 
placebo). Gastrointestinal-related complaints were the most 
common TEAEs, with nausea being particularly common in 
all three groups (40.1% 200 mg/day, 32.6% 100 mg/day and 
21.1% placebo). Higher rates of constipation and vomiting 
were also seen in active treatment groups, as were increased 
rates of headache, hyperhidrosis, hot flush, heart rate increase 
and palpitation. These TEAEs are typical for patients taking 
norepinephrine active medications, and, on average, there 
were no clinically relevant changes in laboratory values, heart 
rate or blood pressure seen in the trials. We have found that 
starting with a low dose of medication, stopping at the dose 
patients find effective, and taking milnacipran with food can 
limit the occurrence of these side effects in the majority of 
FMS patients.
Milnacipran’s place in FMS 
management
With three FDA-approved medications for FMS manage-
ment, deciding which medication to use first in individual 
FMS patients can be challenging since all three indicated 
medications have shown similar efficacy in improving FMS 
pain. We recommend milnacipran as the first-line medica-
tion for FMS patients who rate Fatigue and/or Fibrofog as 
the symptoms that are most limiting for them. This recom-
mendation is based on our clinical experience and the fact 
that milnacipran is the only FDA approved FMS treatment 
shown to improve symptoms of fatigue and cognitive 
dysfunction in phase 3 clinical trials.33,36 Also, our clinical 
experience shows that many patients who have previously 
failed to respond to either of the other two indicated 
medications can have an excellent therapeutic response 
to milnacipran. Despite side effects such as headache, 
gastrointestinal complaints, hyperhidrosis, hypertension 
or palpitations that can limit use in FMS patients, gradual 
uptitration of milnacipran starting with 12.5 mg once in the 
morning can maximize tolerability. However, it is important 
to note that the vast majority of subjects in the milnacipran 
trials and in our clinical practice are Caucasian women, 
making generalization of these recommendations to other 
patient populations problematic. Unfortunately, all trials of 
the indicated FMS drugs have primarily studied Caucasian 
women. New FMS trials in minorities and men are needed 
to determine whether these recommendations are valid for 
all FMS patients.
We have purposely limited the scope of our discussion 
of milnacipran to its role in managing FMS since that is 
the only FDA approved indication in the US. However, 
milnacipran has demonstrated clinical efficacy in treating 
major depressive disorder (MDD) and has been used for 
this indication in Europe and Japan for a decade.50 In the 
treatment of MDD, milnacipran shows similar efficacy to 
the tricyclic antidepressants but with better tolerability.51 The 
relative efficacy of milnacipran in managing MDD compared 
to other antidepressant classes remains unknown.52 While 
not indicated in the US, we have found milnacipran to be a 
reasonable treatment alternative for managing FMS patients 
with coexisting MDD who fail duloxetine therapy.
Conclusions and key points
•  The FIBRO mnemonic can be used to recall FMS 
symptoms including Fatigue, Fibrofog, Insomnia, Blues, 
Rigidity, and Ow! for pain and work disability.
•  Effective FMS treatment requires an individualized pro-
gram of pharmacologic and nonpharmacologic treatments 
(including graduated aerobic and resistance exercise) that 
target problematic FIBRO symptoms.
•  Serotonin and norepinephrine play important roles in 
central pain processing, and FMS patients have reduced 
levels of norepinephrine and serotonin in their cerebro-
spinal fluid.
•  Milnacipran is a balanced NSRI with demonstrated 
efficacy in managing global FMS symptoms and pain at 
doses of 100 and 200 mg divided twice daily.
•  Milnacipran is associated with numerous side effects 
including gastrointestinal complaints, headache, hyper-
hidrosis, hypertension and palpitations.Journal of Pain Research 2010:3 23
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•  Milnacipran tolerability can be maximized by gradual 
uptitration and by taking milnacipran with food.
•  Milnacipran may be particularly beneficial for FMS 
patients with significant symptoms of Fatigue, Fibrofog 
and/or depression.
•  Milnacipran use has been linked to elevations in liver 
function tests and severe liver injury. We recommend 
regular lab monitoring and avoiding milnacipran use in 
patients with chronic liver disease or concomitantly with 
hepatotoxic substances.
•  Unlike duloxetine, milnacipran can be used in patients 
with severe renal disease at 50% of the indicated dose.
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